Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 5
Submit an article Journal homepage
190
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Hepatitis B reverse seroconversion despite entecavir prophylaxis in a myeloma patient on multiple novel agents: a case report and review of the literature

Gemma Reynoldsa Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, AustraliaCorrespondence[email protected], [email protected]
,
Tamasine Stewartb Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia
,
Simon J. Harrisonb Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia;c Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia
,
Andrew Spencerd Department of Malignant Haematology and Stem Cell Transplantation, Alfred Health, Melbourne, Australia
&
Benjamin W. Teha Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia;c Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia;e National Centre for Infections in Cancer, Melbourne, AustraliaORCID Iconhttps://orcid.org/0000-0003-0213-5470
ORCID Icon
Pages 1271-1274 | Received 16 Jul 2020, Accepted 18 Nov 2020, Published online: 04 Dec 2020

References

  • Torresi J. Hepatitis b antiviral resistance and vaccine escape: two sides of the same coin. Antivir Ther. 2008;13(3):337–340.
  • Tsukune Y, Sasaki M, Komatsu N. Reactivation of hepatitis b virus in patients with multiple myeloma. Cancers (Basel). 2019;11(11):1819.
  • Girmenia C, Cavo M, Offidani M, et al. Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations. Blood Rev. 2019;34:84–94.
  • Tsukune Y, Sasaki M, Odajima T, et al. Incidence and clinical background of hepatitis b virus reactivation in multiple myeloma in novel agents’ era. Ann Hematol. 2016;95(9):1465–1472.
  • Tsukune Y, Sasaki M, Odajima T, et al. Incidence and risk factors of hepatitis b virus reactivation in patients with multiple myeloma in an era with novel agents: a nationwide retrospective study in japan. Blood Cancer J. 2017;7:631.
  • Moreau P, Chanan-Khan A, Roberts AW, et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory mm. Blood. 2017;130(22):2392–2400.
  • Brioli A, Klaus M, Sayer H, et al. The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey. Ann Hematol. 2019;98(3):713–722.
  • Ataca Atilla P, Yalciner M, Atilla E, et al. Hepatitis b reactivation rate and fate among multiple myeloma patients receiving regimens containing lenalidomide and/or bortezomib. Turk J Haematol. 2019;36(4):266–273.
  • Maschmeyer G, De Greef J, Mellinghoff SC, et al. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the european conference on infections in leukemia (ecil). Leukemia. 2019;33(4):844–862.
  • Moreau P, Harrison S, Cavo M, et al. Updated analysis of bellini, a phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood. 2019;134(Supplement_1):1888–1888.
  • Zhang TY, Chen HY, Cao JL, et al. Structural and functional analyses of hepatitis b virus x protein bh3-like domain and bcl-xl interaction. Nat Commun. 2019;10(1):3192.
  • Hepatitis B Management During Cancer Therapy Consensus Statement Group. Hepatitis B management during immunosuppression for haematological and solid-organ malignancies; an Australian consensus statement 2019. Melbourne: Hepatitis B Management During Cancer Therapy Consensus Statement Group.
  • Loomba R, Liang TJ. Hepatitis b reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. 2017;152(6):1297–1309.
  • Huang H, Li X, Zhu J, et al. Entecavir vs lamivudine for prevention of hepatitis b virus reactivation among patients with untreated diffuse large b-cell lymphoma receiving r-chop chemotherapy: a randomized clinical trial. JAMA. 2014;312(23):2521–2530.
  • Huang Y-H, Hsiao L-T, Hong Y-C, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis b virus reactivation in patients with lymphoma and resolved hepatitis b. J Clin Oncol. 2013;31(22):2765–2772.
  • Chang T, Wu S, Desmond P, et al. Long-term follow-up of entecavir treated protocol-defined ‘non-responders’ in rollover study etv-901. J Gastroenterol Hepatol. 2008;23:A30–A.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.